Two engineering research centers run by businesses that have settled in the Taizhou Medical High-tech Zone, located in Taizhou city in East China's Jiangsu province, were recently upgraded to provincial-level engineering research centers.
They are the Jiangsu Peptide Drug Separation and Purification Engineering Research Center being operated by Yaohai Bio-Pharma and the Jiangsu Minimally Invasive Surgical Medical Device Engineering Research Center which is run by Jiangsu Baining Yingchuang Medical Technology.
Founded in 2010, Yaohai Bio-Pharma is a platform-based enterprise specializing in Contract Development Manufacturing Organization, or CDMO services for microbial expression systems.
In recent years, it has grown into a leading player in the field of microbial expression system services, serving over 200 projects.
Jiangsu Baining Yingchuang Medical Technology was established in 2018, focusing on the research and development of high-end medical devices.
Its product lines mainly include intraoperative nerve monitoring devices, as well as energy instruments, rotary biopsy and medical suture devices.
Currently, the zone is home to 83 municipal engineering research centers and 27 provincial-level engineering research centers.
Moving forwards, plans are for the zone to continue to guide resident companies to strengthen their R&D and breakthrough core technologies, and overall independent technological innovation capabilities and market competitiveness.
A closer look at the Jiangsu Peptide Drug Separation and Purification Engineering Research Center. [Photo/Taizhou Medical High-tech Zone via WeChat account weigg6666]